Joshua Lehrer-Graiwer
Net worth: 3 M $ as of 2024-04-29
Profile
Joshua Lehrer-Graiwer formerly worked at Graphite Bio, Inc., as President, CEO, CFO, CAO & Director in 2023 and Global Blood Therapeutics, Inc., as Chief Medical Officer from 2019 to 2020.
Dr. Lehrer-Graiwer received his undergraduate degree from Harvard University, graduate degree from the University of Cambridge, and doctorate degree from The University of California, San Francisco.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.65% | 2024-01-31 | 165,953 ( 0.65% ) | 3 M $ | 2024-04-29 |
Former positions of Joshua Lehrer-Graiwer
| Companies | Position | End |
|---|---|---|
| LENZ THERAPEUTICS, INC. | Chief Executive Officer | 2023-08-20 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2020-04-16 |
Training of Joshua Lehrer-Graiwer
| University of Cambridge | Graduate Degree |
| Harvard University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Joshua Lehrer-Graiwer
